Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
69.6M
-
Number of holders
-
132
-
Total 13F shares, excl. options
-
62.3M
-
Shares change
-
+4.92M
-
Total reported value, excl. options
-
$734M
-
Value change
-
+$59M
-
Put/Call ratio
-
0.02
-
Number of buys
-
70
-
Number of sells
-
-39
-
Price
-
$11.77
Significant Holders of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) as of Q3 2025
151 filings reported holding PHAT - Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q3 2025.
Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) has 132 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 62.3M shares
of 69.6M outstanding shares and own 89.57% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (12.5M shares), Medicxi Ventures Management (Jersey) Ltd (7.46M shares), MILLENNIUM MANAGEMENT LLC (5.08M shares), Invesco Ltd. (3.86M shares), Carlyle Group Inc. (3.5M shares), BlackRock, Inc. (3.4M shares), VANGUARD GROUP INC (3.22M shares), Ensign Peak Advisors, Inc (2.5M shares), NEA Management Company, LLC (1.96M shares), and 683 Capital Management, LLC (1.82M shares).
This table shows the top 132 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.